Effectiveness of Psychosocial Intervention on Distress, Body Image Satisfaction and Quality of Life among Colorectal Cancer Patients: An Intervention Study - NIL

开始日期2024-07-03

申办/合作机构

Malabar Cancer Centre

CTRI/2024/02/063180

/ Not yet recruitingN/AIIT

double lumen tube for lung isolation in Indian population:applicability of size prediction based on internationally derived formulas - nil

开始日期2024-03-26

申办/合作机构

Malabar Cancer Centre

100 项与 Malabar Cancer Centre 相关的临床结果

登录后查看更多信息

0 项与 Malabar Cancer Centre 相关的专利（医药）

登录后查看更多信息

205

项与 Malabar Cancer Centre 相关的文献（医药）

2025-07-01·CANCER LETTERS

Phase 3 randomized study of physician choice vs metronomic chemotherapy in platinum refractory/ineligible head and neck cancer in palliative setting with survival outcomes

Article

作者: Khatwani, Itesh ; Modi, Gaurang ; Pathak, Anand ; Wilson, Lovin ; Thavarool, Sajith Babu ; Karpe, Ashay ; Gupta, Tara Chand ; Rajamanickam, Deepan ; Turkar, Siddharth ; Shenoy Vp, Praveen Kumar ; Singh, Gunjesh ; Jadhav, Monica ; Prabhash, Kumar ; Mandal, Tanmoy Kumar ; Bhosale, Bharat ; Jha, Bhavya ; Pande, Nikhil ; Katna, Rakesh ; Poladia, Bhavesh ; Talreja, Vikas T ; Chandrasekharan, Arun ; Bhagyavant, Priyanka ; Rajamanickam, Saravana ; Avaronnan, Manuprasad ; Das, Sudeep ; Muley, Sonal ; Singh, Unnati ; Sonwani, Vaibhav ; Madankar, Kamlesh ; Peelay, Zoya ; Raut, Nirmal ; Kolkur, Manali ; Alone, Mitali ; Patil, Vijay ; Noronha, Vanita ; Pathak, Shruti ; Sen, Nibedita ; Kothari, Rushabh ; Singh, Ravikant ; Kumar, Gautam ; Banavali, S D ; Bhatt, Palak ; Madala, Ravi Krishna ; Shrirangwar, Sameer

There are multiple options of treatment in second line therapy for locally advanced head and neck squamous cell carcinoma (LAHNSCC) treated with palliative intent. However, triple metronomic chemotherapy is oral, cost-effective, and resource-efficient. Hence this phase 3 randomized trial compares National Comprehensive Cancer Network (NCCN) recommended physician choice therapy versus triple metronomic chemotherapy (TMC) in the second-line treatment of head and neck cancer This study, designed to establish superiority, was conducted in India across 16 sites under the Cancer Research Statistics Foundation. The study recruited 114 LAHNSCC who were treated with palliative intent in second line. These patients underwent 1:1 central stratified randomization to either triple metronomic chemotherapy or physician choice therapy (taxane, 5fu/capecitabine, afatinib, nivolumab/pembrolizumab, cetuximab).At a median follow-up of 258 (95 % CI 209-306) days, the median overall survival of the triple metronomic chemotherapy was 181 days (95 %CI 142.7-219.2) versus 123 days (95 %CI 94-152) in the physician choice therapy arm (P = 0.00.002). The median progression free survival was 120 days (95 %CI 89.2-150.8) versus 70 days (95 % CI 58.2-81.8) in metronomic chemotherapy and in the physician choice therapy arms respectively (P < 0.001).These results suggest that TMC significantly improves survival outcomes over physician choice therapy in platinum-refractory head and neck cancer.

2025-07-01·SUPPORTIVE CARE IN CANCER

Knowledge, attitude, and practices in febrile neutropenia among nurses at a tertiary care cancer center in rural India

Article

作者: T K, Jithin ; Nair, Chandran K ; Raghavan, Vineetha ; R, Nandini Devi ; K G, Gopakumar ; Shenoy, Praveen Kumar ; P, Sajitha ; Menon, Abhilash ; K, Ratheesan

PURPOSE:

Febrile neutropenia (FN) is a major cause of morbidity and mortality in chemotherapy patients. Nurses play a vital role in FN management, yet studies assessing their knowledge, attitude, and practices (KAP) in India are limited. This study aimed to evaluate KAP among nurses in a rural Indian tertiary cancer center.

METHODOLOGY:

This cross-sectional KAP survey involved 111 staff nurses at a tertiary cancer center in rural India from October to November 2022. A validated questionnaire with 17 multiple-choice questions (five knowledge, five attitude, seven practice) was used. Demographic and professional details were collected.

RESULTS:

Among 111 participants, 86.4% were female, and 55% had over 10 years of experience. Most (93%) had administered chemotherapy, and 78% had cared for FN patients. The median knowledge score was 4 (range 1-7), with an 80.36% prevalence. Only 61% correctly calculated the absolute neutrophil count. Better scores were seen among permanent staff, those who had attended FN classes, and those with prior FN care experience. The median attitude score was 5 (range 2-7), with a 90.09% prevalence of positive attitude. Nurses with prior chemotherapy administration experience and FN care experience had better scores.The median practice score was 6 (range 1-7), with a 78.42% prevalence. A key gap was identified, as 77% answered incorrectly regarding blood culture sampling during FN episodes. Nurses who attended FN educational classes scored better.

CONCLUSION:

Although nurses' knowledge and attitudes were found to be satisfactory, there are noticeable gaps in their practice, especially when it comes to blood culture sampling, which suggests that focused educational programs are necessary. Improving FN management results requires strengthening practical skills through training, simulations, and protocol reinforcement.

2025-07-01·ARCHIVES OF ORAL BIOLOGY

Immunohistochemical expression of p53/TP53 in histologically negative mucosal margins of head and neck squamous cell carcinomas and usefulness in predicting locoregional recurrence: A systematic review and meta-analysis

Review

作者: Narayanan, Anand Vijaya ; Kamboj, Mala ; Vijayakumar, Gopikrishnan ; Narwal, Anjali ; Nayanar, Sangeeta K ; Aravind, Sithara ; Kumar, Adarsh

OBJECTIVE:

To compare the expression of p53/TP53 in histologically negative mucosal margins of head and neck squamous cell carcinoma with locoregional recurrence.

DESIGN:

A complete search through MEDLINE by PubMed, Google Scholar, Scopus and EMBASE until 31st January 2023, without period restriction. Articles on head and neck squamous cell carcinoma and p53/TP53 expression were included. Sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratio, Odds and relative risk ratio of p53/TP53 in histologically negative surgical margins and its effectiveness in predicting recurrences were derived and subjected to meta-analysis using Open Meta analyst for Sierra (10.12) software.

RESULTS:

The specificity of p53 immunohistochemistry in predicting locoregional recurrence was 0.844 (95 % CI:0.78 ± 0.89) (p-value- < 0.001) with a negative likelihood ratio of 0.487 (95 % CI: 0.35 ± 0.67) (p-value < 0.001) and positive likelihood ratio of 3.032 (95 % CI: 2.17 ± 4.22) (p-value < 0.001). The relative risk of locoregional recurrence in the histologically negative surgical margin with p53 positivity was 3.13 with statistical significance (Odds ratio: 5.249, CI:3.176 ± 8.676, p-value < 0.001). Subgroup meta-analysis based on the location of head and neck SCC shows significant prediction for recurrence in p53 positive margins with more significant results in laryngeal carcinoma recurrence (p value < 0.001) (overall p value < 0.000).

CONCLUSIONS:

Immunohistochemical expression of p53 in histologically negative surgical margins of head and neck squamous cell carcinoma is a significant predictor of locoregional recurrence and prognosis.

项与 Malabar Cancer Centre 相关的新闻（医药）

2024-01-19

·Healthcare IT News

Robotic surgery trickles down to India’s public health sector

The Regional Cancer Centre in Kerala's capital Thiruvananthapuram has reportedly received $7 million in funding to put up a robotic surgery facility, which is a first in a public hospital in India. Inaugurated this week, the robotic surgery unit was established through the Rebuild Kerala Initiative. The same programme is helping set up a similar facility at Malabar Cancer Centre. WHY IT MATTERS Until recently, robot-assisted surgery (RAS) as part of cancer treatment is only accessible in big hospitals in the country and abroad. In the state of Kerala, only three health institutions offer the service, namely Apollo Adlux Hospital, Amrita Hospital, and Aster Medcity – all using the da Vinci Surgical System by American company Intuitive Surgical. THE LARGER TREND As mentioned, robotic surgery, which is regarded for lesser pain, shorter hospital stays and quicker recovery for patients, is largely offered in major and private hospitals and health facilities. The Apollo Institute of Robotic Surgery of Apollo Hospitals and Max Healthcare's Max Institute of Robotic Surgery offer the largest robotic surgery programmes in the country, making use of different robotic surgery systems including da Vinci, Renaissance Robotic Technology, and CORI Surgical System by Smith+Nephew. The private Venkateshwar Hospital in Delhi adopts the Hugo RAS System while another private institution, Swagat Hospitals in India's northeast, runs a robotic surgery theatre featuring CMR Surgical's Versius System. As early as 2002, RAS has been done in India, mostly using Intuitive's da Vinci system, which remains the local market leader. This type of procedure is commonly done in areas such as gastrology, urology, and gynaecology. Some spinal and cardiothoracic operations have also been performed using robotic systems. This year, the Indian RAS market is reportedly projected to be worth around $300 million . Intuitive India's general manager and vice president Mandeep Singh Kumar in a media interview said they are expecting a post-COVID surge in demand for RAS , noting that some are coming from standalone hospitals and hospitals outside tier-1 cities that are also looking to benefit from shorter recovery times it provides. Taking a piece out of this growing market with a more affordable alternative, Dr Sudhir Srivastava, a cardiologist who previously worked on the Da Vinci system, has come out with the locally made SSI Mantra. Priced just about a third of Intuitive's offering, the SSI Mantra was first commercially launched in 2021 and is targeting to make and sell over 1,000 units by the end of the decade. It is currently installed and live at five hospitals in the country: Rajiv Gandhi Cancer Institute in New Delhi, Continental Hospital in Hyderabad, Sanjeevani CBCC USA Cancer Hospital in Raipur, Hindustan Hospital in Coimbatore and Cytocure Hospital in Mumbai.

100 项与 Malabar Cancer Centre 相关的药物交易

登录后查看更多信息

100 项与 Malabar Cancer Centre 相关的转化医学

登录后查看更多信息